세계의 보조생식기술(ART) 시장 : 유형별, 최종사용자별 - 예측

Assisted Reproductive Technology Market size is expected to record a 6.9% CAGR between 2024 and 2032, driven by rising infertility rates influenced by lifestyle factors, such as stress, age, and environmental changes. Technologies, including in vitro fertilization IVF and intrauterine insemination IUI are enabling individuals and couples to overcome fertility challenges.

Assisted reproductive technology ART methods are widely developed to enhance success rates and minimize risks for patients. Moreover, the integration of new technologies and improved protocols are expanding the capabilities of ART for providing hope for individuals struggling with infertility, further reinforcing its role as a vital option in reproductive healthcare. According to a report by WHO, around 17.5% of the adult population globally is experiencing infertility. This is underscoring the critical necessity for several technologies, to expand access to affordable and high-quality fertility care.

The ART industry is segmented into type, end-user/provider, and region.

The market share from the product type segment is expected to witness substantial growth through 2032 due to a strong need for helping individuals and couples achieve their dreams of parenthood by addressing fertility challenges. ART is incorporated with advanced techniques like in vitro fertilization IVF and intracytoplasmic sperm injection ICSI for offering more personalized and effective solutions as well as integrating genetic screening and innovative treatments. As researchers are discovering new ways to enhance success rates, ART products are becoming more accessible and refined.

In terms of end-user/provider, the assisted reproductive technology market from the hospitals segment is slated to generate notable revenue during 2024-2032. This is favored by rising demand by specialists who are utilizing techniques, such as genetic screening, and cryopreservation to improve success rates and patient outcomes. Hospitals are advancing ART by integrating cutting-edge innovations like AI and gene editing to enhance diagnostic accuracy and treatment efficacy for making fertility treatments more efficient and less invasive.

Asia Pacific assisted reproductive technology industry size is likely to record a notable growth rate through 2032 driven by rising disposable incomes along with surging healthcare investments for enhancing the quality and accessibility of these services. Governments and private sectors are pouring resources into healthcare infrastructure for ensuring state-of-the-art facilities and advanced technologies, adding to the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of infertility across population base
    • 3.2.1.2 Demographical shift towards acceptance of assisted reproductive technology (ART)
    • 3.2.1.3 Technological advancements in assisted reproductive technology
    • 3.2.1.4 Rising awareness regarding assisted reproductive technology
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of procedures
    • 3.2.2.2 Social barriers and lack of advanced infrastructure in emerging countries
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Pricing analysis, 2021 - 2032
  • 3.6.1 Procedure pricing analysis, by region
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Product
  • 5.2.1 Media
  • 5.2.2 Catheters
  • 5.2.3 Needles
  • 5.2.4 Vitrification devices
  • 5.2.5 Incubators
  • 5.2.6 Other products
• 5.3 Procedure
  • 5.3.1 By type
    • 5.3.1.1 Fresh donor
    • 5.3.1.2 Fresh nondonor
    • 5.3.1.3 Frozen donor
    • 5.3.1.4 Frozen nondonor
  • 5.3.2 By technology
    • 5.3.2.1 In-vitro fertilization (IVF)
      • 5.3.2.1.1 IVF with intracytoplasmic sperm injection (ICSI)
      • 5.3.2.1.2 IVF without ICSI
    • 5.3.2.2 Artificial insemination - intrauterine insemination (AI-IUI)

Chapter 6 Market Estimates and Forecast, By End-User/Provider, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hospitals
• 6.3 Fertility clinics
• 6.4 Other end-users/providers

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 Japan
  • 7.4.2 China
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
  • 7.5.4 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Egypt
  • 7.6.3 Rest of Middle East and Africa

Chapter 8 Company Profiles

• 8.1 Esco Micro Pte. Ltd
• 8.2 Gynotec
• 8.3 Hamilton Thorne Ltd.
• 8.4 Indira IVF Hospital Private Limited
• 8.5 Ivy Fertility
• 8.6 Kitazato Corporation
• 8.7 Laboratoire CCD
• 8.8 Liverpool Partners Group
• 8.9 Merck KGaA
• 8.10 MISTRAL FERTILITY CLINICS S.L.
• 8.11 NidaCon International AB
• 8.12 Sumitomo Mitsui Financial Group, Inc.
• 8.13 The Cooper Companies, Inc.
• 8.14 Thermo Fisher Scientific Inc.
• 8.15 Vitrolife Group
• 8.16 Western Fertility Institute